The apparently low frequency of TP53 mutations identified in the present patient cohort (1 in 14 patients) may not be considered representative of t-MN in general, since it is the result of the particularly restrictive patient selection, which included only patients with a previous history of hematological malignancies, and available bone marrow samples prior to t-MN development. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.